A double-blind placebo-controlled evaluation of the effect of topical sildenafil on erectile dysfunction

Journal of Applied Research

Volumn 5, Issue 2, 2005, Pages 289-294

  Yonessi, Mehdi ^a   Saeedi, Madjid ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adverse effect; Erectile dysfunction; Sildenafil; Topical; Transdermal

Indexed keywords

PLACEBO; SILDENAFIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FORMULATION; DYSPEPSIA; ERECTILE DYSFUNCTION; GEL; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; POWDER; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; TABLET FORMULATION; VISUAL DISORDER;

EID: 21844470976     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Thomas JA. Pharmacological aspects of erectile dysfunction. Jpn J Pharmacol. 2002;89:101-112.
2. Khan MA, Mikhailidis DP, Morgan RJ. Sildenafil: urologist's view. Curr Med Res Opin. 2000;16(suppl 1):S48-S58.
3. Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED. Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology. 2000;56:474-476.
4. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate in the treatment of erectile dysfunction. Int J Import Res. 1998;10:69-74.
5. Birch DG, Toler SM, Swanson WH, Fish GE, Laties AM. A double-blind placebo-controlled evaluation of the acute effects of sildenafil citrate (Viagra) on visual function in subjects with early-stage age-related macular degeneration. Am J Ophtalmol. 2002;133:665-672.
6. Kloner RA, Zusman RM. Cardiovascular effects of sildenafil citrate and recommendations for its use. Am J Cardiol. 1999;84:11N-17N.
7. Kloner RA. Cardiovascular risk and sidenafil. Am J Cardiol 2000;86:57F-61F.
8. Shakir SA, Wilton LV, Boshier A, Layton D, Heeley E. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ. 2001;322:651-652.
9. Shuster J. Priapism with sildenafil citrate. Hasp Pharm. 2000;35:937.
10. Chen JS. Comparison of FDA reports of patient deaths associated with sildenafil and with injectable alprostadil. Ann Pharmacother. 2001;35:285-288.
11. Flores-Murrieta FJ, Castaneda-Hernandez G. Granados-Soto V, Herrera JE. Increased bioavailability of sildenafil in Mexican men. JAMA. 2000;283:1825-1826.
12. Liaw J, Chang TW. Determination of transdermal sildenafil in nude skin by reversed-phase high-performance liquid chromatography. J Chromatogr B. 2001;765:161-166.
13. Mitragotri S. Synergistic effect of enhancers for transdermal drug delivery. Pharm Res. 2000;17:1354-1359.
14. Altiokka G, Atkosar Z, Sener E, Tuncel M. FIA of sildenafil citrate using UV-detection. J Pharm Biomed Anal. 2001;25:339-342.
15. Anon A. Formulations. Indian J Nat Prod. 2001;5:373-383.
16. Saeedi M, Morteza-Semnani K, Ghoreishi MR. The treatment of atopic dermatitis with licorice gel. J Dermatolog Treat. 2003;14;153-157.
17. McVary Y. Topical agents and erecile dysfunction: is there a place? Curr Urolog Rep. 2002;3:471-476.